133 related articles for article (PubMed ID: 11932909)
1. Trimodality treatment in Stage III nonsmall cell lung carcinoma: prrognostic impact of K-ras mutations after neoadjuvant therapy.
Broermann P; Junker K; Brandt BH; Heinecke A; Freitag L; Klinke F; Berdel WE; Thomas M
Cancer; 2002 Apr; 94(7):2055-62. PubMed ID: 11932909
[TBL] [Abstract][Full Text] [Related]
2. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women.
Nelson HH; Christiani DC; Mark EJ; Wiencke JK; Wain JC; Kelsey KT
J Natl Cancer Inst; 1999 Dec; 91(23):2032-8. PubMed ID: 10580029
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer.
Graziano SL; Gamble GP; Newman NB; Abbott LZ; Rooney M; Mookherjee S; Lamb ML; Kohman LJ; Poiesz BJ
J Clin Oncol; 1999 Feb; 17(2):668-75. PubMed ID: 10080613
[TBL] [Abstract][Full Text] [Related]
4. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.
Schiller JH; Adak S; Feins RH; Keller SM; Fry WA; Livingston RB; Hammond ME; Wolf B; Sabatini L; Jett J; Kohman L; Johnson DH
J Clin Oncol; 2001 Jan; 19(2):448-57. PubMed ID: 11208838
[TBL] [Abstract][Full Text] [Related]
5. Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.
Huang CL; Taki T; Adachi M; Konishi T; Higashiyama M; Kinoshita M; Hadama T; Miyake M
Int J Oncol; 1998 Mar; 12(3):553-63. PubMed ID: 9472092
[TBL] [Abstract][Full Text] [Related]
6. Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma.
Cho JY; Kim JH; Lee YH; Chung KY; Kim SK; Gong SJ; You NC; Chung HC; Roh JK; Kim BS
Cancer; 1997 Feb; 79(3):462-7. PubMed ID: 9028355
[TBL] [Abstract][Full Text] [Related]
7. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma.
Jassem J; Jassem E; Jakóbkiewicz-Banecka J; Rzyman W; Badzio A; Dziadziuszko R; Kobierska-Gulida G; Szymanowska A; Skrzypski M; Zylicz M
Cancer; 2004 May; 100(9):1951-60. PubMed ID: 15112277
[TBL] [Abstract][Full Text] [Related]
8. A modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCLC patients.
Hatzaki A; Razi E; Anagnostopoulou K; Iliadis K; Kodaxis A; Papaioannou D; Labropoulos S; Vasilaki M; Kosmidis P; Saetta A; Mihalatos M; Nasioulas G
Mol Cell Probes; 2001 Oct; 15(5):243-7. PubMed ID: 11735295
[TBL] [Abstract][Full Text] [Related]
9. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
[TBL] [Abstract][Full Text] [Related]
10. A novel molecular staging protocol for non-small cell lung cancer.
Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
[TBL] [Abstract][Full Text] [Related]
11. K-ras gene point mutation: a stable tumor marker in non-small cell lung carcinoma.
Li S; Rosell R; Urban A; Font A; Ariza A; Armengol P; Abad A; Navas JJ; Monzo M
Lung Cancer; 1994 Jul; 11(1-2):19-27. PubMed ID: 8081702
[TBL] [Abstract][Full Text] [Related]
12. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
[TBL] [Abstract][Full Text] [Related]
13. Low mutational rate of K-ras codon 12 in singular bronchoscopy specimens in suspected lung cancer.
Spasova I; Novotna H; Vachtenheim J; Bartosova H; Patek J; Hoserova V; Zatloukal P; Kinkor Z
Neoplasma; 2005; 52(3):255-9. PubMed ID: 15875089
[TBL] [Abstract][Full Text] [Related]
14. Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study.
Rodenhuis S; Boerrigter L; Top B; Slebos RJ; Mooi WJ; van't Veer L; van Zandwijk N
J Clin Oncol; 1997 Jan; 15(1):285-91. PubMed ID: 8996154
[TBL] [Abstract][Full Text] [Related]
15. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.
Kern JA; Slebos RJ; Top B; Rodenhuis S; Lager D; Robinson RA; Weiner D; Schwartz DA
J Clin Invest; 1994 Feb; 93(2):516-20. PubMed ID: 7906694
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection.
Isobe T; Hiyama K; Yoshida Y; Fujiwara Y; Yamakido M
Jpn J Cancer Res; 1994 Dec; 85(12):1240-6. PubMed ID: 7852188
[TBL] [Abstract][Full Text] [Related]
17. [Detection of K-ras oncogene activation in human lung cancer and its possible clinical application].
Zhang G; Sun Y; Wang M
Zhonghua Jie He He Hu Xi Za Zhi; 1995 Oct; 18(5):282-4, 317. PubMed ID: 8762479
[TBL] [Abstract][Full Text] [Related]
18. K-ras gene mutations in non-small cell lung cancer in Japanese.
Noda N; Matsuzoe D; Konno T; Kawahara K; Yamashita Y; Shirakusa T
Oncol Rep; 2001; 8(4):889-92. PubMed ID: 11410804
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis.
Meng D; Yuan M; Li X; Chen L; Yang J; Zhao X; Ma W; Xin J
Lung Cancer; 2013 Jul; 81(1):1-10. PubMed ID: 23608713
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.
Friedel G; Budach W; Dippon J; Spengler W; Eschmann SM; Pfannenberg C; Al-Kamash F; Walles T; Aebert H; Kyriss T; Veit S; Kimmich M; Bamberg M; Kohlhaeufl M; Steger V; Hehr T
J Clin Oncol; 2010 Feb; 28(6):942-8. PubMed ID: 20100967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
